Cilostazol has demonstrated potential as a pharmacological agent for treating both PAD and diabetic neuropathy due to its ability to inhibit phosphodiesterase-3A, promote vasodilation, inhibit platelet aggregation, and increase cAMP levels. The gene discussed is PDE3A; the disease is peripheral arterial disease.